The Landscape of Diabetes Trials in 2026
Diabetes management trials in the United States fall into three broad buckets: drug studies, device studies, and care-delivery studies. Each answers a different question, and each demands a different level of commitment.
Drug trials have dominated the headlines. The SURPASS-CVOT trial, which enrolled more than 13,000 participants across 30 countries, compared the incretin medicines tirzepatide and dulaglutide head-to-head in people with type 2 diabetes and established heart disease. Results published in late 2025 showed tirzepatide reduced the combined rate of cardiovascular death, heart attack, and stroke by an estimated 8% relative to dulaglutide, with meaningful weight loss and better glycemic control on top. That finding led to a broader FDA-approved indication for tirzepatide in adults with type 2 diabetes at high cardiovascular risk.
Device studies are moving just as fast. Closed-loop insulin delivery, sometimes called the artificial pancreas, has evolved from an engineering concept into commercially available hybrid systems. Across randomized trials, automated insulin delivery consistently improves time in range and cuts overnight hypoglycemia, particularly for younger patients. Researchers are now testing more adaptive algorithms that combine continuous glucose monitoring with meal detection and, eventually, multi-hormone systems.
A third category often gets overlooked. The CGM and remote patient monitoring study running at Community Health Center of Franklin County in Massachusetts targets adults with type 2 diabetes and an A1c above 8%, a group that traditional trials frequently miss. Participants receive real-time continuous glucose monitors, weekly check-ins, and endocrinology e-consults. This kind of research matters because it tests whether advanced monitoring works outside academic medical centers, in clinics that serve uninsured and underinsured patients.
What Participation Actually Looks Like
Many people assume joining a trial means weeks in a hospital. In reality, most diabetes studies operate on a far lighter footprint. The AMAZE 2 weight-loss and type 2 diabetes study run by Novo Nordisk, for example, asks participants to maintain their current oral diabetes medications while receiving an investigational injectable. Visits happen at local research sites from Birmingham, Alabama, to Walnut Creek, California. A type 1 diabetes diet study at Boston Children's Hospital delivers study meals to participants' homes for 12 weeks and keeps in-person visits to five weekday appointments, most lasting one to two hours.
Eligibility varies by design, but common threads run through most protocols. Drug trials typically require an A1c in a specific range, a minimum diabetes duration, and stable medication doses before screening. Device trials often require current use of a CGM or insulin pump. Care-delivery trials usually have broader criteria but exclude pregnancy, active cancer treatment, and certain mental health conditions.
Compensation is handled case by case. Some studies reimburse travel and parking, while others offer stipends for time. The Boston Children's study lists compensation up to $1,300 along with free meal delivery and medical supervision. The American Diabetes Association advises that payment policies vary and should be explained during the informed consent process. Anyone can withdraw from a study at any time without penalty.
A Closer Look at Common Trial Types
| Trial category | Example | Typical commitment | Who qualifies | Main benefit | Watch-outs |
|---|
| Incretin drug trial | AMAZE 2 (Novo Nordisk) | 18+ months, monthly visits | Adults 18+, T2D for 6+ months, A1c 7-10% | Access to new GLP-1 based therapy | Injections, GI side effects |
| Cardiovascular outcomes trial | SURPASS-CVOT follow-ups | Multiyear, quarterly visits | T2D with heart disease or risk factors | Proven heart-risk reduction | Long time commitment |
| Closed-loop insulin device | Hybrid AID system studies | 3-6 months, device training | Type 1 or insulin-using T2D | Better time in range, fewer lows | Device cost after trial ends |
| Diet intervention | Boston Children's ketogenic diet study | 12 weeks, meals delivered | Age 18-40, T1D, A1c 6.5-9% | Structured meals, close supervision | Strict diet rules |
| Remote monitoring | Safety-net CGM study (Franklin County, MA) | 24-52 weeks | Adults, T2D, A1c >8% | Free CGM and specialist support | Only at select community clinics |
Regional Access Points and Practical Guidance
Geographic access shapes who can realistically join a trial. Texas has become a hub for diabetes research, with recruiting sites in San Antonio, Seabrook, Weslaco, Dallas, and Houston. The CAPTAIN-T2D study at the Diabetes & Glandular Disease Clinic in San Antonio specifically targets people with type 2 diabetes who are already on multiple injectable or oral medications but still run an A1c of 7.5% or higher. California hosts multiple AMAZE 2 sites from Escondido to Lomita, while Florida research networks in Jacksonville, Orlando, and Oviedo recruit heavily. The Midwest and South Atlantic regions also have active centers in Minneapolis, Spartanburg, and Richmond.
Finding a study near you does not require a medical degree. Start with your own doctor, since they know your history and can flag whether a trial fits your treatment plan. Search ClinicalTrials.gov by condition and ZIP code, and use the American Diabetes Association's clinical trial resources, which explain what informed consent covers and what questions to ask. Before signing anything, confirm who pays for study-related tests and treatments, whether your regular diabetes medications continue during the trial, and what happens to device access after the study ends.
The Human Side of Research Participation
Exit interviews from the SURPASS-CVOT trial offer a rare window into what participants actually experienced. Of the 74 people interviewed, nearly all reported improved glycemic control, 92% described weight reduction, and 78% noticed reduced appetite. Beyond lab numbers, 57% said they felt more energy, and 65% reported better eating habits that persisted after the trial. Some participants noted improvements in conditions unrelated to diabetes, including sleep apnea and joint pain. These accounts matter because they capture outcomes that statistics alone miss.
Trials are also becoming more intentional about inclusion. The Franklin County CGM study exists precisely because underserved populations have been underrepresented in diabetes research for decades. By embedding monitoring tools in a safety-net clinic and pairing them with e-consults from endocrinologists, the study tests a care model that could scale to hundreds of similar clinics nationwide.
Before You Enroll
Ask your care team these four questions before committing to any protocol. First, is this study an option for my specific diabetes type and A1c level? Second, what are the possible benefits and risks for me personally, not just for the study population? Third, how would the trial affect my current medications and insurance coverage? Fourth, who covers study-related tests, travel, and any devices I will be asked to use?
If standard treatments have not gotten you to your goals, or you want early access to therapies not yet widely available, a trial may be a reasonable path. The informed consent process exists to walk you through every risk and benefit in plain language. Read it slowly, take it home, and bring a family member to the screening visit if that helps. Research participation is voluntary from start to finish, and leaving a study early never carries a penalty.
Diabetes management has changed more in the last two years than in the previous decade. The medicines, devices, and care models now being tested in American clinics will shape how the condition is treated for years to come. For the person sitting in an endocrinology waiting room in San Antonio or a community clinic in Massachusetts, that future is closer than it seems.
研究の知恵